| Literature DB >> 26668752 |
Natsumi Takeyama1, Hiroshi Kiyono2, Yoshikazu Yuki3.
Abstract
It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.Entities:
Keywords: GMP-compliant; human vaccine; plant transformation; plant-based vaccine; veterinary vaccine
Year: 2015 PMID: 26668752 PMCID: PMC4667769 DOI: 10.1177/2051013615613272
Source DB: PubMed Journal: Ther Adv Vaccines ISSN: 2051-0136